Howard I. Maibach

In January 2010, Howard I. Maibach, MD, KOL in the field of Dermatology and Dermatopharmacology, joined Olatec’s Scientific Advisory Board and Drug Development Team. Dr. Maibach has been contributing leading strategic expertise to clinical development and market positioning of dapansutrile, as well as in the areas of topical drug development and dermal toxicology. Dr. Maibach is a board certified physician with over 50 years of experience in dermatology in medical practice, academic and commercial settings. Dr. Maibach is a Professor of Dermatology at the University of California, San Francisco School of Medicine. He has vast experience with drug development programs, with a specific focus on preclinical and clinical protocol development for topical products. He has written and lectured extensively on dermatotoxicology (the toxicity to man from skin exposure) and dermatopharmacology (the treatment of skin diseases). During his career Dr. Maibach has held positions in the field of dermatology and pioneered research in the area of dermatotoxicology. He is a member of American College of Physicians, American Academy of Dermatology and American Dermatological Association. He is on the editorial board of journals including International Journal of Dermatology, Recent Advances in Dermatology, Journal of Clinical Research and Pharmacoepidemiology, Journal of European Academy of Dermatology and Venereology, Journal of Applied Toxicology and Clinical Therapeutic. He has published over 2,400 articles dealing with dermatological topics. Dr. Maibach holds an MD from Tulane University, two honorary PhDs from L’Universite de Paris-Sud and Université Claude Bernard Lyon and an AB completed at Tulane University.